NorthStar Medical Radioisotopes, a nuclear medicine company based out of Madison, Wis., announced that it has received approval to begin producing the radioisotope molybdenum-99 (Mo-99).
NorthStar Medical Radioisotopes, a nuclear medicine company based out of Madison, Wis., announced that it has received approval to begin producing the radioisotope molybdenum-99 (Mo-99).
The company will now work on establishing a weekly production schedule at the University of Missouri Research Reactor (MURR) facility in Columbia, Mo.
Mo-99 is the precursor of technetium-99m (Tc-99m), the radioisotope commonly used for medical diagnostic imaging. Interest in the domestic production of Mo-99 has increased in recent years, especially after the news that Canada’s National Research Universal reactor—where 40 percent of the world’s Mo-99 is produced—is scheduled to close in March 2018.
Read the full article here.